RESUMO
ABSTRACT: Patients suffering from substance use disorder, including for instance benzodiazepines, may have comorbidity with attention deficit hyperactivity disorder (ADHD). Centrally acting stimulants play an important role in the treatment of ADHD. Before such treatment can be initiated, withdrawal of benzodiazepines may be necessary. Urine testing is the preferred method for monitoring adherence in benzodiazepine withdrawal, but there is a lack of studies reporting detection time. Here, we report a case of a 30-year-old woman with substance use disorder and ADHD who had detectable metabolites of diazepam 79 days after withdrawal. To our knowledge, no cases with detection time equivalent to this have previously been published. This case report serves as an example that clinicians may need to consider interindividual pharmacokinetic characteristics when interpreting the results of urine drug tests, and that a positive urine test may still be consistent with abstinence from a certain drug. In the current case, a high body mass index and a genetic polymorphism gave a reasonable explanation for the prolonged detection of diazepam metabolites.
Assuntos
Síndrome de Abstinência a Substâncias , Transtornos Relacionados ao Uso de Substâncias , Adulto , Benzodiazepinas/efeitos adversos , Diazepam/efeitos adversos , Diazepam/farmacocinética , Feminino , Humanos , Oxazepam/efeitos adversos , Síndrome de Abstinência a Substâncias/diagnóstico , Síndrome de Abstinência a Substâncias/etiologia , Transtornos Relacionados ao Uso de Substâncias/complicaçõesRESUMO
BACKGROUND: Cognitive reappraisal is a strategy for emotional regulation, important in the context of anxiety disorders. It is not known whether anxiolytic effects of benzodiazepines affect cognitive reappraisal. AIMS: We aimed to investigate the effect of 25 mg oxazepam on cognitive reappraisal. METHODS: In a preliminary investigation, 33 healthy male volunteers were randomised to oxazepam or placebo, and then underwent an experiment where they were asked to use cognitive reappraisal to upregulate or downregulate their emotional response to images with negative or neutral emotional valence. We recorded unpleasantness ratings, skin conductance, superciliary corrugator muscle activity, and heart rate. Participants completed rating scales measuring empathy (Interpersonal Reactivity Index, IRI), anxiety (State-Trait Anxiety Inventory, STAI), alexithymia (Toronto Alexithymia Scale-20, TAS-20), and psychopathy (Psychopathy Personality Inventory-Revised, PPI-R). RESULTS: Upregulation to negative-valence images in the cognitive reappraisal task caused increased unpleasantness ratings, corrugator activity, and heart rate compared to downregulation. Upregulation to both negative- and neutral-valence images caused increased skin conductance responses. Oxazepam caused lower unpleasantness ratings to negative-valence stimuli, but did not interact with reappraisal instruction on any outcome. Self-rated trait empathy was associated with stronger responses to negative-valence stimuli, whereas self-rated psychopathic traits were associated with weaker responses to negative-valence stimuli. CONCLUSIONS: While 25 mg oxazepam caused lower unpleasantness ratings in response to negative-valence images, we did not observe an effect of 25 mg oxazepam on cognitive reappraisal.
Assuntos
Ansiolíticos/efeitos adversos , Cognição/efeitos dos fármacos , Regulação Emocional/efeitos dos fármacos , Oxazepam/efeitos adversos , Adolescente , Adulto , Ansiolíticos/farmacologia , Humanos , Masculino , Oxazepam/farmacologia , Percepção VisualRESUMO
Anthropogenic pharmaceutical pollutants have been detected in nature across the globe, and recent work has shown negative effects of pharmaceuticals on the health and welfare of many animals. However, whether alterations can be reversed has been poorly investigated, although such studies are essential to assess the effects of high-peak exposure events in waterways where pharmaceutical concentrations are usually low. In this study, we investigated the effects of two concentrations (environmentally relevant 1⯵gâ¯L-1 and high 100⯵gâ¯L-1) of oxazepam, an anxiolytic commonly detected in aquatic environments, and whether behavioural alterations are reversible after depuration. Specifically, we measured daytime and night-time swimming activity and daytime behaviours related to boldness (foraging, sheltering and routine swimming activity) using the freshwater burbot (Lota lota). We found that both swimming activity and boldness were affected by oxazepam. Fish exposed to the higher level had a higher burst swimming duration (i.e., fast swimming bouts), both in the daytime and night-time trials. Further, fish exposed to the lower oxazepam level spent less time sheltering than control- and high-level exposed fish, but there was no difference between the control and high oxazepam treatments. For routine swimming activity, quantified in the boldness trials, and for latency to forage, there were no treatment effects. When retesting the fish after depuration, the detected behavioural alterations were no longer present. Since the magnitude of these effects were not consistent across endpoints, our study suggests that oxazepam might not be a great concern for this particular, stress tolerant, species, highlighting the importance of evaluating species-specific effects of pharmaceuticals. The observation that the effects we did find were reversible after depuration is encouraging, and indicates that rapid restoration of behaviours after removal from oxazepam contamination is possible.
Assuntos
Comportamento Alimentar/efeitos dos fármacos , Gadiformes/fisiologia , Oxazepam/efeitos adversos , Natação , Poluentes Químicos da Água/efeitos adversos , Animais , Ansiolíticos/efeitos adversos , Comportamento Animal/efeitos dos fármacos , Relação Dose-Resposta a Droga , Gadiformes/metabolismo , Distribuição AleatóriaRESUMO
With the ability to resist biodegradation and exert therapeutic effects at low concentrations, pharmaceutical contaminants have become environmental stressors for wildlife. One such contaminant is the anxiolytic oxazepam, a psychoactive pharmaceutical that is frequently detected in surface waters globally. Despite growing interest in understanding how wildlife respond to anxiolytics, synergistic effects of pharmaceuticals and other abiotic (e.g. temperature) and biotic (e.g. predation risk) stressors remain unclear. Here, using a multi-stressor approach, we investigated effects of 7-day oxazepam exposure (6.5⯵g/L) on anxiety-related behaviours in juvenile European perch (Perca fluviatilis). The multi-stressor approach was achieved by exposing perch to oxazepam at two temperatures (10⯰C and 18⯰C), and at two predation risk regimes-generated using chemical cues from the northern pike (Esox lucius). Our exposures resulted in a successful uptake of the drug from the water, i.e., oxazepam was measured in perch muscle tissue at 50⯱â¯17â¯ng/g (mean⯱â¯SD). We found significant oxazepam-induced effects on boldness, with 76.7% of the treated fish entering the white background (i.e. 'exposed' area where exposure to presumed risks are higher) within the first 5â¯min, compared to 66.6% of the control fish. We also found a significant effect of temperature on total time spent freezing (i.e. staying motionless). Specifically, fish in the low temperature treatments (oxazepam, predation) froze for longer than fish in high temperatures. Our multi-stressor study is the first to uncover how anxiety-related behaviours in wild juvenile fish are altered by changes in water temperature and perceived predation risk. Importantly, our findings highlight the need to focus on multiple stressors to improve understanding of how organisms not only survive, but adapt to, human-induced environmental change.
Assuntos
Ansiolíticos/efeitos adversos , Ansiedade , Oxazepam/efeitos adversos , Percas/fisiologia , Comportamento Predatório , Poluentes Químicos da Água/efeitos adversos , Animais , Esocidae/fisiologia , Distribuição Aleatória , Estresse Fisiológico , TemperaturaRESUMO
High-dose baclofen is prescribed as a maintenance treatment to reduce alcohol use in patients with alcohol use disorder. Nevertheless, some patients still have massive alcohol intakes and require inpatient alcohol withdrawal. To compare the oral dose of benzodiazepine prescribed to manage alcohol withdrawal symptoms in patients with vs. without steady-state pretreatment with high-dose baclofen. Retrospective chart review study. Prescribed benzodiazepine dose expressed in diazepam-equivalent was compared between groups. Thirty-one patients were assessed in the high-dose maintenance baclofen group and compared to 31 matched patients not receiving baclofen. No statistically significant difference was evident between groups regarding levels of benzodiazepines prescribed. The mean diazepam-equivalent dose during the first 7 days was 294 ± 149 mg in the baclofen group vs. 310 ± 133 mg (t-test = 0.440, P = 0.661) in matched controls. Steady-state high-dose baclofen before an inpatient alcohol cessation hospitalization does not lower the needed benzodiazepine dose in the management of alcohol withdrawal symptoms.
Assuntos
Consumo de Bebidas Alcoólicas/prevenção & controle , Alcoolismo/tratamento farmacológico , Baclofeno/administração & dosagem , Diazepam/administração & dosagem , Moduladores GABAérgicos/administração & dosagem , Agonistas dos Receptores de GABA-B/uso terapêutico , Pacientes Internados , Oxazepam/administração & dosagem , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Administração Oral , Adulto , Consumo de Bebidas Alcoólicas/efeitos adversos , Consumo de Bebidas Alcoólicas/fisiopatologia , Consumo de Bebidas Alcoólicas/psicologia , Alcoolismo/diagnóstico , Alcoolismo/fisiopatologia , Alcoolismo/psicologia , Baclofeno/efeitos adversos , Diazepam/efeitos adversos , Feminino , Moduladores GABAérgicos/efeitos adversos , Agonistas dos Receptores de GABA-B/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Oxazepam/efeitos adversos , Estudos Retrospectivos , Síndrome de Abstinência a Substâncias/diagnóstico , Síndrome de Abstinência a Substâncias/fisiopatologia , Síndrome de Abstinência a Substâncias/psicologia , Fatores de Tempo , Resultado do TratamentoRESUMO
OBJECTIVES: Toxicodynetics aims at defining the time-course of major clinical events in drug overdose. We report the toxicodynetics in mono-intoxications with oxazepam and nordiazepam. METHODS: Cases of oxazepam or nordiazepam overdoses collected at the Paris poison control centre from 1999 to 2014 on the basis of self-report. A particular attention was paid to eliminate the concomitant alcohol or psychotropic co-ingestions. The toxicodynetic parameters were assessed as previously described. Results are expressed using 10-90 percentiles. In adults, the dose was normalized (TI, toxic Index) by dividing the supposed ingested dose by the maximal recommended dose. RESULTS: Two hundred and fifty-one and 74 cases of oxazepam and nordiazepam poisonings were included, respectively. The Emax for oxazepam and nordiazepam were sleepiness or obtundation in 106 and 36 cases, respectively. Coma was used to qualify only one oxazepam overdose. The median delay in onset of the Emax was 1.5h (0.33-15) in nordiazepam and 4h (0.5-15) in oxazepam overdose. In both overdoses, the onset of Emax occurred on an "on-off" mode. In adults, the greatest TIs in nordiazepam and oxazepam overdoses were 45 and 26.7, respectively. The TI in the oxazepam-induced coma was 26.7, the largest dose. CONCLUSION: Data collected in PCC allow determining a number of toxicodynetic parameters. Toxicodynetics showed that nordiazepam is not a cause of coma even in large overdose while oxazepam causes coma only at a very high dose. Deep coma in nordiazepam overdose whatever the dose and deep coma in overdose with oxazepam involving TI less than 20 result from unrecognized drug-drug interaction.
Assuntos
Overdose de Drogas/metabolismo , Moduladores GABAérgicos/efeitos adversos , Moduladores GABAérgicos/farmacocinética , Nordazepam/efeitos adversos , Nordazepam/farmacocinética , Oxazepam/efeitos adversos , Oxazepam/farmacocinética , Toxicocinética , Adolescente , Adulto , Envelhecimento/metabolismo , Depressores do Sistema Nervoso Central/efeitos adversos , Criança , Pré-Escolar , Etanol/efeitos adversos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Adulto JovemRESUMO
Benzodiazepine drugs are controversial because of safety and abuse liability concerns, although they have clinically relevant pharmacological differences. The current article reviews studies pertaining to the pharmacology, safety, and abuse liability of oxazepam. Compared to other benzodiazepine drugs, oxazepam has a favorable safety and abuse liability profile, which may be related to its pharmacology. Oxazepam is more slowly absorbed and enters the brain more slowly than other benzodiazepine drugs; it does not have active metabolites and does not accumulate with chronic dosing; its metabolism is not affected by age or by mild/moderate liver disease; and it is not prone to drug-drug interactions. Oxazepam also binds to the translocator protein, which stimulates the synthesis of neurosteroids, and this effect may contribute to its reduced abuse liability.
Assuntos
Benzodiazepinas/farmacologia , Moduladores GABAérgicos/farmacologia , Oxazepam/farmacologia , Benzodiazepinas/efeitos adversos , Benzodiazepinas/classificação , Moduladores GABAérgicos/efeitos adversos , Humanos , Oxazepam/efeitos adversos , Segurança/legislação & jurisprudência , Transtornos Relacionados ao Uso de Substâncias/prevenção & controleRESUMO
The carcinogenicity of benzodiazepines (BZDs) is still unclear. We aimed to assess whether long-term benzodiazepines use is risk for cancer.We conducted a longitudinal population-based case-control study by using 12 years from Taiwan National Health Insurance database and investigated the association between BZDs use and cancer risk of people aged over 20 years. During the study period, 42,500 cases diagnosed with cancer were identified and analyzed for BZDs use. For each case, six eligible controls matched for age, sex, and the index date (ie, free of any cancer in the date of case diagnosis) by using propensity score. For appropriate risk estimation, we observed the outcomes according to their length of exposure (LOE) and defined daily dose (DDD). To mimic bias, we adjusted with potential confounding factors such as medications and comorbid diseases which could influence for cancer risk during the study period. The data was analyzed by using Cox proportional hazard regression and conditional logistic regression.The finding unveils benzodiazepines use into safe and unsafe groups for their carcinogenicity. The use of diazepam (HR, 0.96; 95%CI, 0.92-1.00), chlorodizepoxide (HR, 0.98; 95%CI, 0.92-1.04), medazepam (HR, 1.01; 95%CI, 0.84-1.21), nitrazepam (HR, 1.06; 95%CI, 0.98-1.14), oxazepam (HR, 1.05; 95%CI, 0.94-1.17) found safer among BZDs. However, clonazepam (HR, 1.15; 95%CI, 1.09-1.22) were associated with a higher risk for cancers. Moreover, specific cancer risk among BZDs use was observed significantly increased 98% for brain, 25% for colorectal, and 10% for lung, as compared with non-BZDs use.Diazepam, chlordiazepoxide, medazepam, nitrazepam, and oxazepam are safe among BZDs use for cancer risk. Our findings could help physicians to select safer BZDs and provide an evidence on the carcinogenic effect of benzodiazepines use by considering the LOE and DDD for further research.
Assuntos
Benzodiazepinas/efeitos adversos , Carcinógenos , Benzodiazepinas/administração & dosagem , Estudos de Casos e Controles , Clordiazepóxido/efeitos adversos , Clonazepam/efeitos adversos , Diazepam/efeitos adversos , Feminino , Humanos , Modelos Logísticos , Estudos Longitudinais , Masculino , Medazepam/efeitos adversos , Pessoa de Meia-Idade , Nitrazepam/efeitos adversos , Oxazepam/efeitos adversos , Modelos de Riscos ProporcionaisRESUMO
Myoclonic status epilepticus or mixed absence-myoclonic status is uncommon in juvenile myoclonic epilepsy (JME), often precipitated by sleep deprivation, withdrawal of medication, or inadequate antiepileptic drugs (Thomas et al., 2006; Crespel et al., 2013). Such episodes respond well to benzodiazepines or valproate (Crespel et al., 2013). We present the video-EEG of a 24-year-old woman with JME and bipolar disorder. She had a confusional state five days after withdrawal of clonazepam (14 mg/d) and introduction of oxazepam (200 mg/d), followed by catatonic stupor with subtle myoclonus of the face and the arms. The EEG showed absence status (figures 1, 2), which stopped after IV injection of clonazepam (1 mg) (figure 3). Consciousness returned to normal [Published with video sequence and figures (1)].
Assuntos
Epilepsias Mioclônicas/etiologia , Epilepsia Mioclônica Juvenil/complicações , Estado Epiléptico/etiologia , Anticonvulsivantes/efeitos adversos , Anticonvulsivantes/uso terapêutico , Transtorno Bipolar/complicações , Catatonia/etiologia , Clonazepam/efeitos adversos , Clonazepam/uso terapêutico , Eletroencefalografia , Feminino , Humanos , Oxazepam/efeitos adversos , Oxazepam/uso terapêutico , Ácido Valproico/uso terapêutico , Adulto JovemRESUMO
INTRODUCTION: Growing evidence shows a high correlation between extensive use of central nervous system-acting drugs (CNSADs) in elderly patients and adverse drug reactions (ADRs) such as falls, fractures, and mortality. RESEARCH QUESTION: Are results of cognitive testing with the Mini Mental Status Examination (MMSE) influenced by use of CNSADs? SETTING: Geriatric inpatient service for acute, subacute, and rehabilitation care. METHODS: Secondary combined analysis of two prospective, single-center study cohorts (PROPSYC, 2011 and AGE OUT, 2012) with identical procedure for the MMSE at a tertiary hospital. RESULTS: Overall, 395 patients were included, 144 male (M) and 251 female (F). Mean age was 80.0 ± 8.4 years (M 76.7 ± 9.1, F 81.9 ± 7.3, p = 0.0000). Mean MMSE points were 22.9 ± 4.8 (M 23.2 ± 4.6, F 22.6 ± 5.0, p = 0.211). In total, 258 patients (65.3 %) used drugs with potential adverse cognitive properties. Analgesics with central activity were given to 117 of 395 patients (29.6 %). Low-potency opioids (tramadol hydrochloride, tilidine) were identified in 60 patients and high-potency opioids in 57 patients. Antidepressants were used in 66 patients, benzodiazepines in 26, and hypnotics in 11, while 38 patients received other CNSADs. We only found significant correlations with the results of cognitive testing for sedatives (diazepam and oxazepam, Pearson's r - 0.79, p = 0.05), but not for lorazepam. CONCLUSION: Our analysis shows an influence of sedatives (diazepam and oxazepam, but not lorazepam) on cognitive testing with the MMSE in users of CNSADs.
Assuntos
Fármacos do Sistema Nervoso Central/efeitos adversos , Transtornos Cognitivos/induzido quimicamente , Hospitalização , Entrevista Psiquiátrica Padronizada , Idoso , Idoso de 80 Anos ou mais , Analgésicos Opioides/efeitos adversos , Analgésicos Opioides/uso terapêutico , Antidepressivos/efeitos adversos , Antidepressivos/uso terapêutico , Benzodiazepinas/efeitos adversos , Benzodiazepinas/uso terapêutico , Fármacos do Sistema Nervoso Central/uso terapêutico , Transtornos Cognitivos/diagnóstico , Diazepam/efeitos adversos , Diazepam/uso terapêutico , Feminino , Humanos , Hipnóticos e Sedativos/efeitos adversos , Hipnóticos e Sedativos/uso terapêutico , Lorazepam/efeitos adversos , Lorazepam/uso terapêutico , Masculino , Oxazepam/efeitos adversos , Oxazepam/uso terapêuticoRESUMO
BACKGROUND: Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS. METHODS: Alcohol-dependent outpatients (n = 126) affected by uncomplicated AWS according to the Clinical Institute Withdrawal Assessment for Alcohol-revised (CIWA-Ar) scale were enrolled in the study and randomized in two groups: 61 patients received SMO and 65 patients received oxazepam for 10 days. The primary endpoint was the reduction of symptoms of AWS measured by the change in the total CIWA-Ar score from baseline (day 1) to the end of the study (day 10). This study is registered with ClinicalTrials.gov, number: NCT02090504 RESULTS: A significant decrease of the mean total CIWA-Ar score from baseline to the end of the study was found in both the SMO (p < 0.0001) and the oxazepam group (p < 0.0001), with no significant differences between the two treatments (p = 0.21). Treatment with SMO and oxazepam resulted in a marked decrease in the severity of the mean CIWA subscales, i.e. sweating, tremor, and anxiety, with no significant differences between the two treatments. Both drugs were well tolerated and no severe side effects were reported. CONCLUSION: SMO is as effective as oxazepam, one of the gold standard BDZs, in the treatment of uncomplicated AWS. Due to its tolerability and absence of significant side effects, SMO may be considered a valid alternative choice in the treatment of AWS.
Assuntos
Alcoolismo/complicações , Oxazepam/uso terapêutico , Oxibato de Sódio/uso terapêutico , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Adulto , Ansiedade/tratamento farmacológico , Ansiedade/fisiopatologia , Fissura/efeitos dos fármacos , Método Duplo-Cego , Feminino , Humanos , Masculino , Oxazepam/efeitos adversos , Índice de Gravidade de Doença , Oxibato de Sódio/efeitos adversos , Síndrome de Abstinência a Substâncias/etiologia , Síndrome de Abstinência a Substâncias/fisiopatologia , Inquéritos e Questionários , Sudorese/efeitos dos fármacos , Resultado do Tratamento , Tremor/tratamento farmacológico , Tremor/fisiopatologiaRESUMO
OVERVIEW: Increasing concerns over the potentially impairing effects of prescriptive sedative drugs such as benzodiazepines on driving have been raised. However, other alternatives such as natural medicines may also carry similar risks with respect to driving safety. Kava (Piper methysticum) is a psychotropic plant commonly used both recreationally and medicinally in the United States, Australia, and the South Pacific to elicit a physically tranquilizing effect. To date no controlled study has tested a medicinal dose of kava versus placebo and a standard sedative drug on driving ability and driving safety. OBJECTIVE: Due to the need to establish the safety of kava in operating a motor vehicle, we compared the acute effects of the plant extract versus the benzodiazepine oxazepam and placebo using a driving simulator. METHODS: A driving simulator (AusEd) was used by 22 adults aged between 18 and 65 years after being randomly administered an acute medicinal dose of kava (180 mg of kavalactones), oxazepam (30 mg), or placebo one week apart in a crossover design trial. RESULTS: No impairing effects on driving outcomes were found after kava administration compared to placebo. Results on specific driving outcome domains revealed that the oxazepam condition had significantly slower braking reaction time compared to the placebo condition (p =.002) and the kava condition (p =.003). The kava condition had significantly fewer lapses of concentration compared to the oxazepam condition (p =.033). No significant differences were found between conditions for steering deviation, speed deviation, and number of crashes. Results were not modified by driving experience. On the Bond-Lader visual analogue sub-scale of alertness, a significant Treatment × Time interaction (p =.032) was found, with a significant reduction over time for oxazepam decreasing alertness (p <.001), whereas no significant reduction was found in the kava or placebo conditions. CONCLUSION: The results indicate that a medicinal dose of kava containing 180 mg of kavalactones does not impair driving ability, whereas 30 mg of oxazepam shows some impairment. Research assessing larger recreational doses of kava on driving ability should now be conducted.
Assuntos
Condução de Veículo/psicologia , Hipnóticos e Sedativos/efeitos adversos , Kava/efeitos adversos , Extratos Vegetais/efeitos adversos , Desempenho Psicomotor/efeitos dos fármacos , Adolescente , Adulto , Idoso , Simulação por Computador , Estudos Cross-Over , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Oxazepam/efeitos adversos , Adulto JovemRESUMO
Although cocaine dependence affects an estimated 1.6 million people in the USA, there are currently no medications approved for the treatment of this disorder. Experiments performed in animal models have demonstrated that inhibitors of the stress response effectively reduce intravenous cocaine self-administration. This exploratory, double-blind, placebo-controlled study was designed to assess the safety and efficacy of combinations of the cortisol synthesis inhibitor metyrapone, and the benzodiazepine oxazepam, in 45 cocaine-dependent individuals. The subjects were randomized to a total daily dose of 500 mg metyrapone/20 mg oxazepam (low dose), a total daily dose of 1500 mg metyrapone/20 mg oxazepam (high dose), or placebo for 6 weeks of treatment. The outcome measures were a reduction in cocaine craving and associated cocaine use as determined by quantitative measurements of the cocaine metabolite benzoylecgonine (BE) in urine at all visits. Of the randomized subjects, 49% completed the study. The combination of metyrapone and oxazepam was well tolerated and tended to reduce cocaine craving and cocaine use, with significant reductions at several time points when controlling for baseline scores. These data suggest that further assessments of the ability of the metyrapone and oxazepam combination to support cocaine abstinence in cocaine-dependent subjects are warranted.
Assuntos
Transtornos Relacionados ao Uso de Cocaína/tratamento farmacológico , Inibidores Enzimáticos/uso terapêutico , Agonistas GABAérgicos/uso terapêutico , Metirapona/uso terapêutico , Oxazepam/uso terapêutico , Esteroide 11-beta-Hidroxilase/antagonistas & inibidores , Síndrome de Abstinência a Substâncias/prevenção & controle , Adulto , Cocaína/análogos & derivados , Cocaína/urina , Transtornos Relacionados ao Uso de Cocaína/prevenção & controle , Transtornos Relacionados ao Uso de Cocaína/urina , Manual Diagnóstico e Estatístico de Transtornos Mentais , Relação Dose-Resposta a Droga , Método Duplo-Cego , Quimioterapia Combinada/efeitos adversos , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/efeitos adversos , Feminino , Agonistas GABAérgicos/administração & dosagem , Agonistas GABAérgicos/efeitos adversos , Humanos , Louisiana , Masculino , Metirapona/administração & dosagem , Metirapona/efeitos adversos , Pessoa de Meia-Idade , Oxazepam/administração & dosagem , Oxazepam/efeitos adversos , Cooperação do Paciente , Pacientes Desistentes do Tratamento , Projetos Piloto , Prevenção Secundária , Esteroide 11-beta-Hidroxilase/administração & dosagem , Esteroide 11-beta-Hidroxilase/efeitos adversosRESUMO
Side-effects arising on the grounds of antidepressant administration pose as a substantial obstacle hindering successful depressive disorder treatment. Side-effects, especially those severe or those manifested through dramatic clinical presentations such as panic attacks, make the treatment far more difficult and shake patients' trust in both the treatment and the treating physician. This case report deals with a patient experiencing a moderately severe depressive episode, who responded to duloxetine treatment administered in the initial dose of 30 mg per day with as many as three panic attacks in two days. Upon duloxetine withdrawal, these panic attacks ceased as well. The patient continued tianeptine and alprazolam treatment during which no significant side-effects had been seen, so that she gradually recovered. Some of the available literature sources have suggested the possibility of duloxetine administration to the end of generalised anxiety disorder and panic attack treatment. However, they are outnumbered by the contributions reporting about duloxetine-related anxiety, aggressiveness and panic attacks. In line with the foregoing, further monitoring of each and every duloxetine-administered patient group needs to be pursued so as to be able to evaluate treatment benefits and weigh them against risks of anxiety or panic attack onset.
Assuntos
Antidepressivos/efeitos adversos , Transtorno de Pânico/induzido quimicamente , Tiofenos/efeitos adversos , Alprazolam/efeitos adversos , Alprazolam/uso terapêutico , Ansiolíticos/efeitos adversos , Ansiolíticos/uso terapêutico , Antidepressivos/uso terapêutico , Antidepressivos Tricíclicos/uso terapêutico , Relação Dose-Resposta a Droga , Esquema de Medicação , Quimioterapia Combinada , Cloridrato de Duloxetina , Feminino , Seguimentos , Humanos , Pessoa de Meia-Idade , Oxazepam/efeitos adversos , Oxazepam/uso terapêutico , Tiazepinas/uso terapêutico , Tiofenos/uso terapêuticoRESUMO
BACKGROUND: Often, long-term treatment with benzodiazepines is a subject of discussion due to potential side effects, with dependence on benzodiazepines as the most serous one. After longer period of benzodiazepines tolerance on their anxiolytic effects develops. Discontinuation is usually beneficial as it is followed by improved psychomotor and cognitive functioning, particularly in the elderly. Previous studies confirmed occurrence of physical dependence in high percentage of patients in long term treatment with benzodiazepines at therapeutic dosages. Benzodiazepines are relatively well-tolerated medicines but can induce serious problems of addiction and that is why their use is regulated. The aim of this article is to report a case of a patient who was taking 15 tablets of oxazepam daily for a period of time, during which reinforcement of irritability occurred. CONCLUSION: It is necessary to warn patients who take benzodiazepines in therapy that reinforcement of irritability may occur in case of higher dosage of benzodiazepines, which may be misinterpreted as worsening in mental condition.
Assuntos
Ansiedade/tratamento farmacológico , Benzodiazepinas/efeitos adversos , Hipnóticos e Sedativos/efeitos adversos , Humor Irritável/efeitos dos fármacos , Acontecimentos que Mudam a Vida , Oxazepam/efeitos adversos , Adulto , Antidepressivos/administração & dosagem , Ansiedade/psicologia , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Tolerância a Medicamentos , Cloridrato de Duloxetina , Humanos , Hipnóticos e Sedativos/administração & dosagem , Masculino , Oxazepam/administração & dosagem , Piridinas/administração & dosagem , Automedicação/psicologia , Tiofenos/administração & dosagem , ZolpidemRESUMO
AIMS: An objective physiological test was used to investigate the hangover effect, its time course and dose relationship compared to placebo and an herbal relaxant. METHODS: Pupillographic Sleepiness Test as an objective measurement, Stanford Sleepiness Scale (SSS) and visual analogue scales (VAS) were used. Study design included: (a) randomised, double-blind, double-dummy, placebo-controlled crossover trial; (b) double-blind, placebo-controlled, randomised study. Primary end point was the Pupillary Unrest Index (lnPUI). RESULTS: Oxazepam 10 mg did not increase PUI. In the VAS and SSS, there was no increase in sleepiness after the three treatment periods. Neither 10 nor 30 mg oxazepam caused sedation in healthy volunteers. Subjective and objective sleepiness measures correlated significantly. DISCUSSION: The lack of sedative effects after vespertine intake of oxazepam (10/30 mg) seems to be relevant with respect to product safety. With regard to the subjective perception at 30 mg, fatigue rather than sleepiness may be the underlying reason.
Assuntos
Sedação Consciente/métodos , Interações Ervas-Drogas/fisiologia , Hipnóticos e Sedativos/efeitos adversos , Oxazepam/efeitos adversos , Vigília/efeitos dos fármacos , Adulto , Estudos Cross-Over , Relação Dose-Resposta a Droga , Feminino , Humanos , Hipnóticos e Sedativos/farmacologia , Masculino , Pessoa de Meia-Idade , Oxazepam/farmacologia , Pupila/efeitos dos fármacos , Fatores de TempoRESUMO
OBJECTIVE: To describe associations between the use of benzodiazepines or related drugs (BZDs/RDs) and health, functional abilities and cognitive function in the elderly. METHODS: A non-randomised clinical study of patients aged > or =65 years admitted to acute hospital wards during 1 month. 164 patients (mean age +/- standard deviation [SD] 81.6 +/- 6.8 years) were admitted. Of these, nearly half (n = 78) had used BZDs/RDs before admission, and the remainder (n = 86) were non-users. Cognitive ability was assessed by the Mini-Mental State Examination (MMSE). Patients scoring > or =20 MMSE sum points were interviewed (n = 79) and questioned regarding symptoms and functional abilities during the week prior to admission. Data on use of BZDs/RDs before admission, current medications and discharge diagnoses were collected from medical records. Health, physical abilities and cognitive function were compared between BZD/RD users and non-users, and adjustments were made for confounding variables. The residual serum concentrations of oxazepam, temazepam and zopiclone were analysed. RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31). Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20). Long-term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS, which tended to be related to diagnosed dementia. After adjustment for these variables as confounders, use of BZDs/RDs was not associated with cognitive function as measured by the MMSE. However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay. Use of BZDs/RDs tended to be associated with a reduced ability to walk and shorter night-time sleep during the week prior to admission. A higher residual serum concentration of temazepam correlated with a lower MMSE sum score after adjustment for confounding variables. CONCLUSIONS: Long-term use and concomitant use of more than one BZD/RD were common in elderly patients hospitalised because of acute illnesses. Long-term use was associated with daytime and night-time symptoms indicative of poorer health and potentially caused by the adverse effects of these drugs.
Assuntos
Benzodiazepinas/efeitos adversos , Transtornos Cognitivos/induzido quimicamente , Cognição/efeitos dos fármacos , Nível de Saúde , Hipnóticos e Sedativos/efeitos adversos , Atividades Cotidianas , Idoso , Idoso de 80 Anos ou mais , Compostos Azabicíclicos/administração & dosagem , Compostos Azabicíclicos/efeitos adversos , Compostos Azabicíclicos/sangue , Benzodiazepinas/administração & dosagem , Benzodiazepinas/sangue , Coleta de Dados , Quimioterapia Combinada , Feminino , Humanos , Hipnóticos e Sedativos/administração & dosagem , Hipnóticos e Sedativos/sangue , Masculino , Oxazepam/administração & dosagem , Oxazepam/efeitos adversos , Oxazepam/sangue , Piperazinas/administração & dosagem , Piperazinas/efeitos adversos , Piperazinas/sangue , Desempenho Psicomotor/efeitos dos fármacos , Fatores Sexuais , Temazepam/administração & dosagem , Temazepam/efeitos adversos , Temazepam/sangueRESUMO
Case histories are based on actual medical negligence claims, however certain facts have been omitted or changed by the author to ensure the anonymity of the parties involved. Medication errors in general practice are relatively common. This article describes a medication error that led to a patient complaint and claim.
Assuntos
Diarreia/induzido quimicamente , Medicamentos Genéricos/efeitos adversos , Erros de Medicação/efeitos adversos , Oxazepam/efeitos adversos , Gestão de Riscos/métodos , Idoso , Anti-Inflamatórios não Esteroides/uso terapêutico , Austrália , Celecoxib , Colchicina/efeitos adversos , Prescrições de Medicamentos , Medicina de Família e Comunidade/legislação & jurisprudência , Medicina de Família e Comunidade/métodos , Feminino , Gota/tratamento farmacológico , Supressores da Gota/uso terapêutico , Humanos , Hipnóticos e Sedativos/efeitos adversos , Erros de Medicação/legislação & jurisprudência , Pirazóis/uso terapêutico , Fases do Sono , Sulfonamidas/uso terapêuticoRESUMO
Although additional dosages of benzodiazepines in long-term users of benzodiazepines are common, it is unknown whether these additional dosages resort any effect. The effects of an additional 20-mg dosage oxazepam were assessed in a double-blind, balanced-order, crossover randomized study comparing 16 long-term users of oxazepam (patients) with 18 benzodiazepine-naive controls (controls). The effects of 10 and 30 mg oxazepam were assessed at pretest and 2.5 hours after drug administration on: (a) saccadic eye movements as proxy for the sedative effect, (b) acoustic startle response (ASR) as proxy for the anxiolytic effects, (c) memory, (d) reaction time tasks, and (e) subjective measurements. Dose-related effects were found in patients on the peak velocity of saccadic eye movement and on response probability, respectively peak amplitude of the ASR. Comparison with controls, however, suggests that in patients the sedative effects might be mixed up with suppression of sedative withdrawal symptoms, whereas patients were as sensitive as benzodiazepine-naive controls for the effects of an additional dosage on the ASR. Neither 10 nor 30 mg oxazepam challenge affected the reaction time tasks in patients, whereas controls show a dose-related impairment. The memory impairing effects, however, did not differ significantly between patients and controls. In contrast to controls, patients could not discriminate between a 10- and 30-mg dosage as assessed by visual analogue scales and the STAI-DY-1, which might indicate a placebo effect in the 10-mg challenge in patients. We conclude that additional dosages of oxazepam still exert pronounced effects after daily use for more than 10 years.
Assuntos
Ansiolíticos/administração & dosagem , Ansiolíticos/uso terapêutico , Ansiedade/tratamento farmacológico , Oxazepam/administração & dosagem , Oxazepam/uso terapêutico , Adulto , Ansiolíticos/efeitos adversos , Ansiedade/psicologia , Estudos Cross-Over , Método Duplo-Cego , Feminino , Humanos , Hipnóticos e Sedativos , Masculino , Transtornos da Memória/induzido quimicamente , Transtornos da Memória/psicologia , Rememoração Mental/efeitos dos fármacos , Pessoa de Meia-Idade , Oxazepam/efeitos adversos , Escalas de Graduação Psiquiátrica , Desempenho Psicomotor/efeitos dos fármacos , Reflexo de Sobressalto/efeitos dos fármacos , Movimentos Sacádicos/efeitos dos fármacosRESUMO
Patients aged 18 to 73 years and diagnosed with non-organic insomnia according to ICD-10 (F 51.0) were treated in a multicentre, double-blind, randomised parallel group comparison with either 600 mg/die valerian extract LI 156 (Sedonium) or 10 mg/die oxazepam taken for 6 weeks. A total of 202 outpatients with a mean duration of insomnia of 3.5 months at baseline were included at 24 study centres (general practices) in Germany. - Sleep quality (SQ) after 6 weeks measured by the Sleep Questionnaire B (SF-B; CIPS 1996) showed that 600 mg/die valerian extract LI 156 was at least as efficacious as a treatment with 10 mg/die oxazepam. Both treatments markedly increased sleep quality compared with baseline (p <0.01). The other SF-B subscales, i.e. feeling of refreshment after sleep (GES), psychic stability in the evening (PSYA), psychic exhaustion in the evening (PSYE), psychosomatic symptoms in the sleep phase (PSS), dream recall (TRME), and duration of sleep confirmed similar effects of both treatments. Clinical Global Impressions scale (CGI) and Global Assessment of Efficacy by investigator and patient, again, showed similar effects of both treatments. Adverse events occurred in 29 patients (28.4%) receiving valerian extract LI 156 and 36 patients (36.0%) under oxazepam, and were all rated mild to moderate. No serious adverse drug reactions were reported in either group. Most patients assessed their respective treatment as very good (82.8% in the valerian group, 73.4% in the oxazepam group). During the 6 week treatment phase Valerian extract LI 156 (Sedonium) 600 mg/die showed a comparable efficacy to 10 mg/die oxazepam in the therapy of non-organic insomnia.